What is Morgan Stanley's price target for ALVR?

Morgan Stanley's latest stated price target for AlloVir Inc. (ALVR) is $45, from its action on Jan 18, 2022.

What is Morgan Stanley's rating on ALVR?

Morgan Stanley rates ALVR Overweight, a bullish rating, as of Jan 18, 2022.

When did Morgan Stanley last change its view on ALVR?

On Jan 18, 2022, Morgan Stanley cuts its price target to $45 from $48, keeps Overweight.

Morgan Stanley ALVR price target and rating history

Morgan Stanley rates AlloVir Inc. (ALVR) Overweight with a $45 price target, as of its latest action on Jan 18, 2022. It has published 5 rating actions on ALVR since August 2021, including 0 upgrades and 0 downgrades.

Current rating: Overweight
Price target: $45
Median target, all firms: Too few
Actions on ALVR: 5

Morgan Stanley price target on ALVR

Morgan Stanley price target on ALVR, each point a stated target, August 2021 to January 2022.

Every Morgan Stanley rating on ALVR

Jan 18, 2022
ReiterateMorgan Stanley cuts its price target to $45 from $48, keeps Overweight
Oct 19, 2021
ResumeMorgan Stanley resumes coverage at Overweight, price target $48
Oct 12, 2021
ReiterateMorgan Stanley raises its price target to $48 from $47, keeps Overweight
Sep 29, 2021
ReiterateMorgan Stanley raises its price target to $225 from $175, keeps Overweight
Aug 18, 2021
ReiterateMorgan Stanley cuts its price target to $47 from $50, keeps Overweight

Questions about Morgan Stanley and ALVR

What is Morgan Stanley's price target for ALVR?: Morgan Stanley's latest stated price target for AlloVir Inc. (ALVR) is $45, from its action on Jan 18, 2022.
What is Morgan Stanley's rating on ALVR?: Morgan Stanley rates ALVR Overweight, a bullish rating, as of Jan 18, 2022.
When did Morgan Stanley last change its view on ALVR?: On Jan 18, 2022, Morgan Stanley cuts its price target to $45 from $48, keeps Overweight.

More ALVR rating histories

Leerink Partners4

All Morgan Stanley ratings ALVR news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.